GLP-1 and GIP medications such as Mounjaro, Zepbound, Wegovy, Ozempic, and Rybelsus have dramatically reshaped the treatment landscape for obesity, diabetes, and metabolic disease. These therapies improve blood sugar, reduce cardiovascular risk, decrease inflammation, and support meaningful and sustained weight and fat reduction.
For many, cost has been the primary barrier. Monthly prices reaching $1,000 or more placed these medications well outside the reach of individuals who needed them most.
Recent announcements from the White House indicate the beginning of major national changes to GLP-1 pricing. Here is what patients should know based on current information.
National GLP-1 Pricing Changes
Cash-Pay Pricing (January 2026)
A new federal purchasing platform is expected to begin offering GLP-1 medications at significantly reduced cash-pay rates—around $350 per month—starting in January 2026.
Medicare & Medicaid (Mid-2026)
Beginning mid-2026, Medicare and Medicaid beneficiaries will see expanded access and lower pricing for GLP-1 medications.
Projected pricing:
• Approximately $245 per month
• Co-pays as low as $50 per month for qualifying patients
This marks a substantial shift, as Medicare has not historically covered obesity-treatment medications.
State-Level Implementation (2027)
Several states will adopt pricing changes later, with full Medicaid implementation expected by 2027 in many regions.
Future Oral GLP-1 Option: Orforglipron
A once-daily oral GLP-1 medication—Orforglipron, developed by Eli Lilly—is currently in late-stage clinical trials. While not yet FDA-approved, it is expected to join reduced pricing tiers once approved.Rybelsus remains the only currently available oral GLP-1, approved for type 2 diabetes.
Why This Matters—and Why Waiting May Not Be the Best Option
The national reforms represent significant progress in making metabolic health treatments more accessible. But these changes are not immediate. Full price reductions will not be available for most people until 2026–2027.
For patients currently experiencing obesity, diabetes, or metabolic decline, delaying treatment can mean:
- Worsening insulin resistance
• Increased cardiovascular risk
• Higher inflammation
• Continued weight gain
• Reduced energy and quality of life
Fortunately, patients do not need to wait years to access safe, effective, medically supervised treatment.
How Achieve Can Help Today
At Achieve Health & Weight Loss, our focus is delivering high-quality, physician-led, safe metabolic care—not simply offering low-cost medications. While national pricing will eventually decrease, Achieve already provides accessible pricing through FDA-registered U.S. pharmacies.
Current Achieve Member Pricing:
- Zepbound – as low as $350 per month
- Mounjaro (Tirzepatide) – as low as $409 per month
- Wegovy – as low as $359 per month
- Ozempic – as low as $359 per month
- Rybelsus (oral semaglutide) – as low as $359 per month
Multiple other GLP-1 and GIP options are available depending on medical need, inventory, and insurance coverage.
But the medication alone is not the solution.
GLP-1 and GIP therapies are powerful tools—but they are only one piece of the puzzle. Real, lasting metabolic health requires:
- Physician oversight
- Accountability
- Coaching
- Behavior change
- Body composition monitoring
- Nutrition and movement guidance
- Safe medication titration
- Evidence-based long-term planning
This is where Achieve stands apart.
What Sets Achieve Apart
Achieve may not always be the absolute cheapest option—and that is intentional.
Low-cost, high-volume online programs often lack medical oversight, skip safety checks, provide little or no coaching, and sometimes source medication from questionable suppliers. These shortcuts can compromise safety, effectiveness, and long-term results.
Achieve is different.
Our program is led by a double board-certified physician in Internal Medicine and Obesity Medicine, a distinction held by fewer than 0.5% of U.S. physicians.
Achieve offers:
- Comprehensive metabolic evaluation
- 1:1 virtual health coaching and support
- Body composition monitoring
- Personalized nutrition, activity, and lifestyle planning
- Safe and responsible medication management
- Secure partnerships with accredited U.S. pharmacies
Our goal is not to be the cheapest—we aim to be the best, safest, and most effective program for long-term metabolic health and sustainable results.
The Bottom Line
National GLP-1 price reductions are coming in the next one to two years, but patients needing treatment today do not have to wait. Achieve Health & Weight Loss already provides safe, affordable access to GLP-1 and GIP medications, supported by a comprehensive medical and coaching program that ensures the best possible health outcomes—not just short-term results.
